Results 331 to 340 of about 369,868 (397)
Some of the next articles are maybe not open access.
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers
Nature Reviews Rheumatology, 2016John D Isaacs
exaly +2 more sources
Best Practice & Research Clinical Obstetrics & Gynaecology, 2023
Expectant management of a cesarean scar pregnancy (CSP) is associated with a high risk of severe maternal morbidity. Therefore, most experts recommend immediate termination after the diagnosis of a CSP. However, there is no consensus about the optimal management of a CSP in terms of efficacy, safety, and preservation of future fertility.
NOEL, Laure, Chantraine, Frédéric
openaire +2 more sources
Expectant management of a cesarean scar pregnancy (CSP) is associated with a high risk of severe maternal morbidity. Therefore, most experts recommend immediate termination after the diagnosis of a CSP. However, there is no consensus about the optimal management of a CSP in terms of efficacy, safety, and preservation of future fertility.
NOEL, Laure, Chantraine, Frédéric
openaire +2 more sources
The Lancet, 1968
SUMMARY. Seventeen patients with widespread psoriasis were treated with parenteral methotrexate over a period of 2–88 weeks. The injections were given every 1–4 weeks, in a dose of 12·5–37·5 mg. The best results were obtained with a dose of 25 mg. of methotrexate once weekly.
H, Baker, T J, Ryan
+9 more sources
SUMMARY. Seventeen patients with widespread psoriasis were treated with parenteral methotrexate over a period of 2–88 weeks. The injections were given every 1–4 weeks, in a dose of 12·5–37·5 mg. The best results were obtained with a dose of 25 mg. of methotrexate once weekly.
H, Baker, T J, Ryan
+9 more sources
Arthritis & Rheumatology, 2019
To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1‐selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an ...
R. Fleischmann +11 more
semanticscholar +1 more source
To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1‐selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an ...
R. Fleischmann +11 more
semanticscholar +1 more source
Pharmacokinetics of Methotrexate and 7-Hydroxy-Methotrexate After Methotrexate Infusions
Cancer Drug Delivery, 1987Methotrexate was administered by IV infusion, 2g (1.19 +/- 0.05 g/m2) over 24 hours, to a homogeneous group of patients undergoing treatment for breast cancer. Three courses were given at three week intervals. Methotrexate and 7-hydroxy-methotrexate plasma and urine pharmacokinetics were investigated. The average terminal half-lives of methotrexate and
P, Bore +4 more
openaire +2 more sources
Clinical and Experimental Dermatology, 1996
Methotrexate is an effective antipsoriatic agent and has been widely used to treat severe psoriasis since the 1960s. It is especially useful in acute generalized pustular psoriasis, psoriatic erythroderma, psoriatic arthritis and for extensive chronic plaque psoriasis in patients who are inadequately controlled by topical therapy alone.
M J, Boffa, R J, Chalmers
openaire +2 more sources
Methotrexate is an effective antipsoriatic agent and has been widely used to treat severe psoriasis since the 1960s. It is especially useful in acute generalized pustular psoriasis, psoriatic erythroderma, psoriatic arthritis and for extensive chronic plaque psoriasis in patients who are inadequately controlled by topical therapy alone.
M J, Boffa, R J, Chalmers
openaire +2 more sources
Home Healthcare Now, 2015
The purpose of this article is to educate healthcare professionals about the many uses of the drug Methotrexate. Information regarding dosing, action, contraindications, adverse effects, drug interactions, as well as tips for patient education are included.
openaire +3 more sources
The purpose of this article is to educate healthcare professionals about the many uses of the drug Methotrexate. Information regarding dosing, action, contraindications, adverse effects, drug interactions, as well as tips for patient education are included.
openaire +3 more sources
Pharmacokinetics of methotrexate
Clinical Pharmacology & Therapeutics, 1973The pharmacokinetics of SH‐methotrexate were studied in 22 patients with malignancies. Following the intravenous administration of 30 mg methotrexate (Mtx) per square meter, the plasma disappearance was triphasic with half‐lifes of 0.7.5 ± 0.11,3.49 ± 0 . .55, and 26.99 ± 4.44 hours, respectively.
D H, Huffman +3 more
openaire +2 more sources
Journal of Medicinal Chemistry, 1979
Analogues of methotrexate (MTX) were prepared by alkylation of side-chain precursors with 6-(bromomethyl)-2,4-pteridinediamine followed, where necessary, by saponification of the intermediate esters and, in two cases, by electrophilic substitution reactions in the pyridine ring portion of 3-deazamethotrexate.
J A, Montgomery +5 more
openaire +2 more sources
Analogues of methotrexate (MTX) were prepared by alkylation of side-chain precursors with 6-(bromomethyl)-2,4-pteridinediamine followed, where necessary, by saponification of the intermediate esters and, in two cases, by electrophilic substitution reactions in the pyridine ring portion of 3-deazamethotrexate.
J A, Montgomery +5 more
openaire +2 more sources